Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 354.37% | 309.60% | 195.75% | -25.51% | -0.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 354.37% | 309.60% | 195.75% | -25.51% | -0.11% |
| Cost of Revenue | 153.16% | 4.84% | 3.41% | -38.00% | -28.26% |
| Gross Profit | -75.00% | 96.42% | 69.78% | 41.80% | 35.34% |
| SG&A Expenses | 237.97% | 9.03% | 11.39% | 38.54% | 19.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.37% | 6.30% | 6.11% | -18.06% | -15.38% |
| Operating Income | -149.89% | 52.49% | 36.24% | 16.50% | 18.01% |
| Income Before Tax | -320.64% | 53.13% | 35.83% | 15.53% | 17.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -321.93% | 51.89% | 34.60% | 15.53% | 17.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -321.93% | 51.89% | 34.60% | 15.53% | 17.17% |
| EBIT | -149.89% | 52.49% | 36.24% | 16.50% | 18.01% |
| EBITDA | -148.96% | 55.51% | 37.95% | 16.58% | 18.09% |
| EPS Basic | -63.33% | 72.33% | 58.22% | 49.70% | 43.46% |
| Normalized Basic EPS | -61.90% | 73.14% | 58.98% | 49.69% | 43.08% |
| EPS Diluted | -63.39% | 72.28% | 58.17% | 49.70% | 43.46% |
| Normalized Diluted EPS | -61.98% | 73.08% | 58.92% | 49.69% | 43.08% |
| Average Basic Shares Outstanding | 84.06% | 79.49% | 68.17% | 74.09% | 52.79% |
| Average Diluted Shares Outstanding | 84.91% | 80.50% | 69.29% | 74.09% | 52.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |